Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10962373 | Vaccine | 2016 | 7 Pages |
Abstract
GMZ2 is the first blood-stage malaria vaccine to be evaluated in a large multicenter trial. GMZ2 was well tolerated and immunogenic, and reduced the incidence of malaria, but efficacy would need to be substantially improved, using a more immunogenic formulation, for the vaccine to have a public health role.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sodiomon B. Sirima, Benjamin Mordmüller, Paul Milligan, Ulysse Ateba Ngoa, Fred Kironde, Frank Atuguba, Alfred B. Tiono, Saadou Issifou, Mark Kaddumukasa, Oscar Bangre, Clare Flach, Michael Christiansen, Peter Bang, Roma Chilengi, Søren Jepsen,